These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 7167065

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Rate of isolation of "C. difficile" from stools of hospitalized patients: susceptibility of 75 strains (author's transl)].
    Tytgat F.
    Ann Microbiol (Paris); 1980; 131B(1):11-20. PubMed ID: 7458111
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Morphological changes in human embryonic lung fibroblasts caused by cytotoxins of various Clostridium species].
    Schallehn G, Wolff MH.
    Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Jan; 267(3):367-78. PubMed ID: 3376617
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial susceptibility of Clostridium difficile from different sources.
    Nakamura S, Nakashio S, Mikawa M, Yamakawa K, Okumura S, Nishida S.
    Microbiol Immunol; 1982 Jan; 26(1):25-30. PubMed ID: 7087801
    [Abstract] [Full Text] [Related]

  • 8. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model.
    Baines SD, O'Connor R, Saxton K, Freeman J, Wilcox MH.
    J Antimicrob Chemother; 2009 Mar; 63(3):520-5. PubMed ID: 19112083
    [Abstract] [Full Text] [Related]

  • 9. Cytotoxin and enterotoxin production by Clostridium difficile.
    Gianfrilli P, Luzzi I, Pantosti A, Occhionero M, Gentile G, Panichi G.
    Microbiologica; 1984 Oct; 7(4):375-9. PubMed ID: 6513801
    [Abstract] [Full Text] [Related]

  • 10. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.
    Freeman J, Baines SD, Saxton K, Wilcox MH.
    J Antimicrob Chemother; 2007 Jul; 60(1):83-91. PubMed ID: 17483547
    [Abstract] [Full Text] [Related]

  • 11. Production and release of toxins A and B by Clostridium difficile.
    Ketley JM, Haslam SC, Mitchell TJ, Stephen J, Candy DC, Burdon DW.
    J Med Microbiol; 1984 Dec; 18(3):385-91. PubMed ID: 6389875
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clostridium difficile in gnotobiotic mice.
    Onderdonk AB, Cisneros RL, Bartlett JG.
    Infect Immun; 1980 Apr; 28(1):277-82. PubMed ID: 7380566
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model.
    Baines SD, O'Connor R, Saxton K, Freeman J, Wilcox MH.
    J Antimicrob Chemother; 2008 Nov; 62(5):1078-85. PubMed ID: 18772161
    [Abstract] [Full Text] [Related]

  • 19. Characterization of a nosocomial Clostridium difficile outbreak by using plasmid profile typing and clindamycin susceptibility testing.
    Clabots CR, Peterson LR, Gerding DN.
    J Infect Dis; 1988 Oct; 158(4):731-6. PubMed ID: 2844914
    [Abstract] [Full Text] [Related]

  • 20. Correlation between serogroup and susceptibility to chloramphenicol, clindamycin, erythromycin, rifampicin and tetracycline among 308 isolates of Clostridium difficile.
    Delmée M, Avesani V.
    J Antimicrob Chemother; 1988 Sep; 22(3):325-31. PubMed ID: 3053559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.